Aims: Poly-ADP-ribose polymerase inhibitors have emerged as a new class of therapeutic agents for breast cancer patients with BRCA mutations; however, the efficacy and toxicity of PARP inhibitors have not been clearly established. Methods: This study comprehensively evaluated the efficacy and safety of PARP inhibitors in BRCA mutated breast cancer patients. Online databases were systematically searched, and six clinical trials were included in the meta-analysis. The primary endpoint of efficacy was PFS, secondary endpoints are OS and ORR. In addition, we also assessed safety. Results: The results of the meta-analysis showed that PARP inhibitors can effectively improve the PFS, and OS of patients compared with the control group. The pooled HR (PARP inhibitor vs control group) was 0.63 (95 % CI, 0.55− 0.73) in PFS and 0.83 (95% CI, 0.73 -0.95) in OS among all patients. In terms of safety, PARP inhibitors show controllable adverse reactions. There were no significant differences in overall AEs or grade≥3 AEs between the PARP inhibitor arms and the control arms. Conclusions: In general, this study demonstrates PARP inhibitors perform well in both monotherapy and combination therapy, not only can provide substantial survival benefit, but also do not increase the additional toxicity burden, and the clinical application is promising.